CNC Quote, Financials, Valuation and Earnings

The Cigna Group has a net margin of 2.81% compared to Centene's net margin of 2.02%. Centene's return on equity of 12.65% beat The Cigna Group's return on equity of 12.17%.

Centene has a consensus price target of $78.09, signalling upside risk potential of 38.37%. On the other hand The Cigna Group has an analysts' consensus of $375.21 which suggests that it could grow by 18.5%. Given that Centene has higher upside potential than The Cigna Group, analysts believe Centene is more attractive than The Cigna Group.

Centene has a beta of 0.478, which suggesting that the stock is 52.18% less volatile than S&P 500. In comparison The Cigna Group has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.821%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cigna Group offers a yield of 1.8% to investors and pays a quarterly dividend of $1.51 per share. Centene pays -- of its earnings as a dividend. The Cigna Group pays out 45.63% of its earnings as a dividend. The Cigna Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Centene quarterly revenues are $46.6B, which are smaller than The Cigna Group quarterly revenues of $65.5B. Centene's net income of $1.3B is lower than The Cigna Group's net income of $1.3B. Notably, Centene's price-to-earnings ratio is 8.41x while The Cigna Group's PE ratio is 17.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.17x versus 0.35x for The Cigna Group. Usually stocks with elevated PS ratios are considered overvalued.

Elevance Health has a net margin of 2.81% compared to Centene's net margin of 4.47%. Centene's return on equity of 12.65% beat Elevance Health's return on equity of 14.03%.

Centene has a consensus price target of $78.09, signalling upside risk potential of 38.37%. On the other hand Elevance Health has an analysts' consensus of $503.49 which suggests that it could grow by 31.17%. Given that Centene has higher upside potential than Elevance Health, analysts believe Centene is more attractive than Elevance Health.

Centene has a beta of 0.478, which suggesting that the stock is 52.18% less volatile than S&P 500. In comparison Elevance Health has a beta of 0.657, suggesting its less volatile than the S&P 500 by 34.296%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Elevance Health offers a yield of 1.72% to investors and pays a quarterly dividend of $1.71 per share. Centene pays -- of its earnings as a dividend. Elevance Health pays out 25.22% of its earnings as a dividend. Elevance Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Centene quarterly revenues are $46.6B, which are smaller than Elevance Health quarterly revenues of $48.9B. Centene's net income of $1.3B is lower than Elevance Health's net income of $2.2B. Notably, Centene's price-to-earnings ratio is 8.41x while Elevance Health's PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.17x versus 0.48x for Elevance Health. Usually stocks with elevated PS ratios are considered overvalued.

Molina Healthcare has a net margin of 2.81% compared to Centene's net margin of 2.67%. Centene's return on equity of 12.65% beat Molina Healthcare's return on equity of 25.66%.

Centene has a consensus price target of $78.09, signalling upside risk potential of 38.37%. On the other hand Molina Healthcare has an analysts' consensus of $360.24 which suggests that it could grow by 18.1%. Given that Centene has higher upside potential than Molina Healthcare, analysts believe Centene is more attractive than Molina Healthcare.

Centene has a beta of 0.478, which suggesting that the stock is 52.18% less volatile than S&P 500. In comparison Molina Healthcare has a beta of 0.633, suggesting its less volatile than the S&P 500 by 36.702%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molina Healthcare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Centene pays -- of its earnings as a dividend. Molina Healthcare pays out -- of its earnings as a dividend.

Centene quarterly revenues are $46.6B, which are larger than Molina Healthcare quarterly revenues of $11.1B. Centene's net income of $1.3B is higher than Molina Healthcare's net income of $298M. Notably, Centene's price-to-earnings ratio is 8.41x while Molina Healthcare's PE ratio is 14.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.17x versus 0.41x for Molina Healthcare. Usually stocks with elevated PS ratios are considered overvalued.

UnitedHealth Group has a net margin of 2.81% compared to Centene's net margin of 5.74%. Centene's return on equity of 12.65% beat UnitedHealth Group's return on equity of 21.74%.

Centene has a consensus price target of $78.09, signalling upside risk potential of 38.37%. On the other hand UnitedHealth Group has an analysts' consensus of $397.36 which suggests that it could grow by 31.62%. Given that Centene has higher upside potential than UnitedHealth Group, analysts believe Centene is more attractive than UnitedHealth Group.

Centene has a beta of 0.478, which suggesting that the stock is 52.18% less volatile than S&P 500. In comparison UnitedHealth Group has a beta of 0.561, suggesting its less volatile than the S&P 500 by 43.865%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UnitedHealth Group offers a yield of 2.78% to investors and pays a quarterly dividend of $2.10 per share. Centene pays -- of its earnings as a dividend. UnitedHealth Group pays out 52.29% of its earnings as a dividend. UnitedHealth Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Centene quarterly revenues are $46.6B, which are smaller than UnitedHealth Group quarterly revenues of $109.6B. Centene's net income of $1.3B is lower than UnitedHealth Group's net income of $6.3B. Notably, Centene's price-to-earnings ratio is 8.41x while UnitedHealth Group's PE ratio is 12.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.17x versus 0.68x for UnitedHealth Group. Usually stocks with elevated PS ratios are considered overvalued.